Adial Pharmaceuticals, Inc.: A Biopharmaceutical Company in the Healthcare Sector
Overview
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product, AD04, is a serotonin-3 antagonist that is currently in Phase III clinical trials for the treatment of alcohol use disorder. In addition to this, Adial Pharmaceuticals is also working on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company, founded in 2010 and headquartered in Charlottesville, Virginia, has 16 full-time employees.
Financial Summary
- Previous Close: $1.35
- Open: $1.33
- Market Cap: $2.271M
- 52 Week Range: $0.77 – $14.00
- Volume: 190,284
- Average Volume: 4,058,200
- PE Ratio (TTM): N/A
- EPS (TTM): -$8.98
- Beta (5Y Monthly): 1.52
- 1 Year Target Estimate: $17.00
Stock Performance
Adial Pharmaceuticals' stock has had a challenging year, with the price dropping from a high of $14.00 to a low of $0.77. The stock's current price is $1.365, with a previous close at $1.35. The company's market cap stands at $2.271M.
Industry and Sector
Adial Pharmaceuticals operates in the biotechnology industry, specifically in the healthcare sector. The company focuses on developing therapeutics for addiction and related disorders, making it a key player in addressing pressing health issues.
Company Leadership
Adial Pharmaceuticals is led by a team of experienced executives, including:
- Mr. Cary John Claiborne MBA (CEO, President & Director)
- Mr. Joseph A. M. Truluck M.B.A., MBA (CFO, Treasurer & Secretary)
- Mr. Tony Goodman (COO & Director)
- Dr. Bankole A. Johnson DSc, FRCPsych, M.D., M.Phil, Ph.D. (Founder & Chief Medical Officer)
- Mr. John R. Martin J.D. (General Counsel)
Conclusion
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for addiction and related disorders. With its lead product in Phase III clinical trials and a pipeline of drug candidates for pain reduction and other diseases, the company is positioned for growth in the healthcare sector. However, the stock's performance has been challenging, with a significant drop in price over the past year. Investors should carefully consider the company's financials and market conditions before making any investment decisions.
